High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa groupA.-L. Taksin, Sylvie Castaigné, Xavier Thomas et al.|Leukemia|2006Cited by 295
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trialAline Renneville, Claude Preudhomme, Raouf Ben Abdelali et al.|Oncotarget|2014Cited by 53